by Tristan Manalac – BioSpace –
Takeda is looking to offload its cell therapy platform and preclinical assets to a yet-unidentified external partner. 137 employees will be let go as part of the move.
Takeda will no longer invest in cell therapies moving forward as the pharma reassesses its pipeline priorities and works to boost the efficiency and productivity of its business.
The Japanese multinational has no active cell therapy clinical trials, according to a Wednesday announcement. In conjunction with the move away from cell therapy, Takeda is looking to offload its cell therapy platform to an external partner, where the company expects the clinic-ready programs will continue to advance. The company is also laying off 137 employees as part of the move, according to reporting from the Boston Business Journal.
